|
| | | | | | | | | | | |
| Name | Indication | Rights | Admin | Approved | Mechanism | IP | | Price | 75 | |
| Orencia (abatacept) | Rheumatoid Arthritis | 1 | IV | 12/23/2005 | CTLA4 mab | Protein | | Shares | 2135.255158 | Q222 |
| Revlimid (lenalidomide) | Multiple Myeloma | | Oral | 12/27/2005 | PROTAC | | | MC | 160144.13685 | |
| Opdivo (nivolumab) | Cancer | Ono | IV | 12/22/2014 | PD-1 mab | Protein | | Cash | 13228 | Q222 |
| Empliciti (elotuzumab) | Myeloma | ABBV | IV | 11/30/2015 | SLAMF7 mab | Protein | | Debt | 42060 | Q222 |
| Reblozyl (luspatercept) | Beta Thalassemia, MDS | MRK | IV | 11/8/2019 | GDF | | | EV | 188976.13685 | |
| Pomalyst (pomalidomide) | Multiple Myeloma | | Oral | 2/8/2013 | PROTAC | | | | | |
| Camzyos (mavacamten) | oHCM | | Oral | | myosin inhibitor | | | | | |
| Opdualag (relatlimab/nivolumab) | Melanoma | | SC | | LAG3 | | | | | |
| Abecma | Multiple Myeloma | | IV | | BCMA CART | | | | | |
| Zeposia (ozanimod) | Multiple Sclerosis | | Oral | | S1P agonist | | | CEO: Giovanni Caforio | | |
| Sprycel (dasatinib) | CML | 1 | Oral | 6/28/2006 | Kinase Inhibitor | NCE | | CFO: David Elkins | | |
| Breyanzi (lisocabtagene maraleucel) | | | IV | | CD19 CART | | | CMO: Samit Hirawat | | |
| Erbitux (cetuximab) | mCRC | 61%-/LLY | IV | 2/12/2004 | Anti-EGFR antibody | Antibody | | CCO: Chris Boerner | | |
| Baraclude (entecavir) | HBV | 1 | Oral | 5/29/2005 | Nucleoside polymerase | 2015 | | | | |
| Eliquis (apixaban) | VTE, DVT, AF, ACS | PFE | Oral | 7/9/2013 | Factor Xa inhibitor | | | | | |
| Sotyktu (deucravacitinib) | Psoriasis | | Oral | 9/9/2022 | TYK2 | | | | | |
| Yervoy (ipilimumab) | Melanoma | MEDX | IV | 3/25/2011 | CTLA4 | Antibody | | | | |
| | | | | Phase | | | | | | |
| iberdomide | Multiple Myeloma | | | | PROTAC | | | | | |
| mezigdomide | Multiple Myeloma | | | | PROTAC | | | | | |
| repotrectinib | NSCLC | | Oral | II/III | ROS1 inhibitor | | | | | |
| milvexian | VTE, DVT, AF, ACS | | | | FXIa inhibitor | | | | | |
| cendakimab | EoE, AD | | | | IL-13 mab | | | | | |
| BMS-582949 | RA, Psoriasis | 1 | Oral? | I/II | | | | | | |
| BMS-986202/AM152 | IPF | 1 | | | | | | | | |
| BMS-767778 | Type 2 Diabetes | 1 | Oral | I | DPPIV inhibitor? | | | | | |
| BMS-777607 | Cancer | 100%/Aslan | Oral | II | MET Inhibitor | | | | | |
| BMS-708163 | Alzheimer's | 1 | Oral | II | Gamma-secretase | | | | | |
| BMS-795311 | Dyslipidemia | 100%/Simcere | Oral | II | CETP | | | | | |
| BMS-741672 | Neuropathic Pain | 1 | Oral | II | CCR2 antagonist | | | | | |
| BMS-626531 | RA | 1 | Oral | I | p38 | | | | | |
| | | | | | | | | | | |
| | | | | | 7/26/19: Positive CHMP opinion for Empliciti | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | January 22nd 2007: Plavix trial begins | | | | | |
| | | | | | ASCO 2008: Erbitux FLEX results. | | | | | |
| | | | | | Mid 08: File saxagliptin (was 1H?) | | | | | |
| | | | | | August 1 2008: Sold Convatec. | | | | | |
| | | | | | July 30th 2009: Onglyza PDUFA. | | | | | |
| | | | | | August 30th 2009: ESC meeting with Plavix results. | | | | | |
| | | | | | 2010: Ipilimumab results. | | | | | |
| | | | | | 2/12: Acquires Inhibitex for 2.5bn. | | | | | |
| | | | | | 6/29/12: Acquires Amylin. | | | | | |
| | | | | | Mead Johnson | | | | | |
| | | | | | Q312: Refile Eliquis? | | | | | |
| | | | | | Q113: Eliquis PDUFA? | | | | | |